Compare BridgeBio Pharma Inc (BBIO) vs British American Tobacco PLC (BTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs British American Tobacco PLC — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while British American Tobacco PLC trades at $56.92 (market cap $122.96B). The key difference: British American Tobacco PLC is far larger — about 7.4× BridgeBio Pharma Inc's market cap, and British American Tobacco PLC pays a 5.85% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | BTI | |
|---|---|---|
Market Cap | $16.61B | $122.96B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $66.70 |
52-Week Low | $47.29 | $50.39 |
Enterprise Value | $18.16B | $166.84B |
Dividend Yield | — | 5.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
BTI trades at $59.33, up 1.02% today, with a bearish technical signal but strong fundamentals including a P/E of 15.15, net income margin of 24.99%, and consistent earnings beats. Recent news highlights growth in next-generation products like Velo, though restructuring and regulatory pressures persist.
The outlook is mixed: valuation appears attractive with a 5%+ dividend yield, but declining operating cash flow and bearish technicals suggest near-term headwinds. Risks include regulatory scrutiny and combustible product declines, while analyst consensus leans bullish with 12 buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →
